FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
Follows Japanese Approval Last September
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
You may also be interested in...
The high-profile antibody-drug conjugate has shown its potential to improve outcomes for heavily pre-treated patients in diseases such as bladder, cervical, pancreatic and rare cancers in a mid-stage trial.
Enhertu secured US FDA approval as a second-line treatment in HER2-positive breast cancer, where it is poised to become the new standard of care.
Transformative product is the first to demonstrate benefit in HER2-low metastatic breast cancer, broadening its market potential to nearly half of all breast cancers.